Harvard University
Harvard University Biostatistics Working Paper Series
Year 

Paper 

Survival analysis with functions of
mis-measured covariate histories: the case of
chronic air pollution exposure in relation to
mortality in the Nurses’ Health Study
Xiaomei Liao∗

Molin Wang†

Francine Laden∗∗

Jaime E. Hart‡

Donna Spiegelman††

∗

Harvard University, stxia@channing.harvard.edu
Harvard University
‡
Harvard University
∗∗
Harvard University
††
Harvard University
This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commercially reproduced without the permission of the copyright holder.
†

http://biostats.bepress.com/harvardbiostat/paper198
Copyright c 2015 by the authors.

Survival analysis with functions of
mis-measured covariate histories: the case of
chronic air pollution exposure in relation to
mortality in the Nurses’ Health Study
Xiaomei Liao, Molin Wang, Jaime E. Hart, Francine Laden, and Donna
Spiegelman

Abstract

Environmental epidemiologists are often interested in estimating the effect of
functions of time-varying exposure histories, such as the 12-month moving average, in relation to chronic disease incidence or mortality. The individual exposure
measurements that comprise such an exposure history are usually mis-measured,
at least moderately, and, often, more substantially. To obtain unbiased estimates
of Cox model hazard ratios for these complex mis-measured exposure functions,
an extended risk set regression calibration (RRC) method for Cox models is developed and applied to a study of long-term exposure to the fine particulate matter ($PM {2.5}$) component of air pollution in relation to all-cause mortality
in the Nurses’ Health Study. Simulation studies under several realistic assumptions about the measurement error model and about the correlation structure of
the repeated exposure measurements were conducted to assess the finite sample
properties of this new method, and found that the method has good performance
in terms of finite sample bias reduction and nominal confidence interval coverage.
User-friendly software has been developed and is available to the general public
on the senior author’s website.
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Abstract
Environmental epidemiologists are often interested in estimating the effect of
functions of time-varying exposure histories, such as the 12-month moving average, in relation to chronic disease incidence or mortality. The individual exposure
measurements that comprise such an exposure history are usually mis-measured,
at least moderately, and, often, more substantially. To obtain unbiased estimates
of Cox model hazard ratios for these complex mis-measured exposure functions, an
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extended risk set regression calibration (RRC) method for Cox models is developed
and applied to a study of long-term exposure to the fine particulate matter (P M2.5 )
component of air pollution in relation to all-cause mortality in the Nurses’ Health
Study. Simulation studies under several realistic assumptions about the measurement error model and about the correlation structure of the repeated exposure
measurements were conducted to assess the finite sample properties of this new
method, and found that the method has good performance in terms of finite sample
bias reduction and nominal confidence interval coverage. User-friendly software has
been developed and is available to the general public on the senior author’s website.
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1

INTRODUCTION

Air pollution (AP) is the 13th leading cause of mortality worldwide (Brook et al., 2004).
The acute effects of AP on mortality have been well documented as far back as 1930
(Pope III, 2000) and evidence indicates that the relationship is both valid and causal
(Dab et al., 2001). Since the late 1980s, numerous studies have found current particulate
air pollutant concentrations to be responsible for excess mortality, with associations with
daily deaths having been reported across the U.S., Europe, Latin America and Asia
(Atkinson et al., 2015, 2014; U.S. EPA., 2004). In addition, a large body of evidence
has formed linking long-term, that is chronic, AP exposure with an increased risk of
cardiovascular (CVD) morbidity and mortality (Hoek et al., 2013; Pope III and Dockery,
2006). In a recent review of the evidence from 11 long-term AP cohort studies, the pooled
effect estimate for each 10 µg/m3 increase in P M2.5 (particulate matter contained in AP
of size fractions up to 2.5 micrometers (µm)) was 6.2% (95%CI: 4.1% - 8.4%) for all-cause
mortality and 10.6% (95%CI: 5.4% -16.0%) for cardiovascular mortality (Hoek et al.,
2013). To put these risks into perspective, in 1988 and 2013, average P M2.5 levels in the
U.S. were 35 µg/m3 and under 10 µg/m3 respectively, while currently in Beijing, China
and Delhi, India, they are approximately 100 µg/m3 and 150 µg/m3 respectively.
In chronic AP epidemiology, the 12-month moving average has been commonly used
2
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(Schwartz et al., 2008). Thus, in the study motivating this methodologic research, the
AP exposure metrics of interest are the 12-month moving averages of P M2.5 , P M10 and
P M2.5−10 , particulate matter contained in AP of size fractions up to 2.5 µm, up to 10 µm,
and between 2.5 and 10 µm (Puett et al., 2008; Hart et al., 2015). The individual exposure data that are used to construct the 12-month P M2.5 moving average exposure were
collected monthly from the nearest Environmental Protection Agency (EPA) Air Quality
System (AQS) monitor, and then estimated from well-established spatio-temporal models
that smooth the EPA monitor measurements over time and space, taking other factors into
account, such as meteorological conditions, as well (Paciorek et al., 2009; Yanosky et al.,
2014). However, neither the measurements from EPA monitors nor the spatio-temporal
smoothed exposure estimates accurately reflect personal exposure to particulate matter
for each individual included in the cohort at each point in time during which they are
under observation. A recent nine city validation study showed that these surrogate individual exposure measurements at a given point in time have moderate to substantial
measurement error, with correlations between these surrogates and direct measures of
personal exposure ranging from 0.29 to 0.60 (Kioumourtzoglou et al., 2014). It should
be noted that the methodology developed here is fully generalizable to any pre-specified
functions of the exposure histories.
To validly and efficiently assess the effect of environmental exposures on health outcomes, exposure measurement error needs to be taken into account or exposure effects
will likely be under- and poorly estimated (Carroll et al., 2006). An additional challenge
in the analysis of AP cohort studies, where the exposure of interest is a function of the
mis-measured exposure history, concerns the mis-alignment of the validation study data
with the data needed to correct the effect estimates to be obtained in the main study for
measurement error, in the following sense: validation studies contain, at most, a small
sample of individual point exposure measurements at several points in time, while, as
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discussed above, the exposure of interest in the main study, is a pre-specified function of
the exposure history. In the data motivating this research, each participant has a series
of surrogate 12-month moving average exposure functions measured over some interval in
their life time, each one of which imperfectly measures its unobserved perfectly measured
counterpart. Validating a sample of these 12-month moving averages over the etiologically
relevant period or even a reasonably sized sub-interval is not possible. Instead of validating the function of the surrogate exposure histories, exposure validation studies in AP
research and, more generally, in environmental health research, are comprised of a sample of point exposures typically observed with few or no repeated measures within each
subject. The methods developed below are designed to accommodate this challenging
common setting.
The regression calibration (RC) method for survival data analysis was first proposed
by Prentice (1982). Further research extended these initial results to a somewhat broader
range of models and measurement error structures and to different study designs that
permit consistent estimation and inference (Rosner et al., 1989, 1990; Spiegelman et al.,
1997; Wang et al., 1997). The original regression calibration method for survival data
analysis assumed that the measurement error model is time-invariant, as is approximately
true when the disease is rare. Otherwise, if the rare disease assumption does not hold, a
risk set regression calibration (RRC) method which allows the measurement error model to
evolve over time and refits at each risk set can be used (Xie et al., 2001). Liao et al. (2011)
further expanded these methods, and addressed measurement error correction for a limited
class of time-varying covariates: time-varying point exposures, and functions of timevarying point exposures when, unrealistically, the validation study has the same frequency
of measurement of time-varying point exposures as in the main study or by assuming,
generally unrealistically, that the measurement error model for the point exposures in
the validation study is fully transportable to the main study for the exposure metric of

4
http://biostats.bepress.com/harvardbiostat/paper198

interest, a time-varying function of the exposure histories of varying duration. Without
making unrealistic assumptions as above, there is no method available to validly estimate
hazard ratios for functions of time-varying mis-measured point exposures with limited
validation data as in this case study.
This paper develops an approximately consistent method for estimating the hazard
ratio for functions of time-varying mis-measured exposure histories, augmented by point
exposure validation data. It is organized as follows. In Section 2, we introduce the motivating example. Then, we develop the new methodology in Section 3. We conduct a
simulation study in Section 4. In Section 5, we apply the proposed method to the analysis
of P M2.5 in relation to all-cause mortality in the Nurses’ Health Study (NHS), described
in Section 2, augmented by the nine city validation study. In Section 6, we conclude with
a discussion of the limitations and strengths of the proposed method, and identify directions for further research. User-friendly software accompanies the new method, and can be
found on the senior author’s website, https://www.hsph.harvard.edu/donna-spiegelman/software/rrc-macro/.

2

APPLICATION: NURSES’ HEALTH STUDY AIR
POLLUTION COHORT AND NINE CITY VALIDATION STUDY

2.1

Nurses’ Health Study Air Pollution Cohort

This study of the chronic health effects of AP is embedded within the NHS, a long-term
prospective cohort study initiated in 1976 when 121,701 married female US registered
nurses, 30 to 55 years old, completed a mailed questionnaire (Colditz and Hankinson,
2005). While participants were initially from eleven states at the study’s inception, the
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participants now reside in all 50 U.S. states. Follow-up questionnaires have been mailed
every two years to obtain updated information on risk factors and on the occurrence of
major illnesses, with response rates above 90% for each mailing, making it possible to
regularly update residential addresses. This study includes the 117,408 participants who
were alive in 1988, when estimates of particulate matter exposure were first available,
and who had at least one address within the continental U.S. between 1988 and 2006 for
which longitude and latitude could be obtained. Non-accidental deaths occuring between
June 1988 through May 2006 were identified through state vital statistics records, the
National Death Index, by report from the families and by the postal system (Colditz et al.,
1986). A nationwide expansion of a geographic information system (GIS)-based spatiotemporal model for P M2.5 was used to compute smoothed monthly P M2.5 exposure at
each participants’ residential address (Paciorek et al., 2009; Yanosky et al., 2014). Based
on the monthly measurements from June 1999 - May 2006, the 12-month moving average
exposures were then calculated.

2.2

Nine City Validation Study

Ideally, P M2.5 exposure would be measured by personal monitors continuously over the
entire follow-up period of each participant. If this were possible, the only exposure measurement error would be technical error associated with the monitoring devices, which is
small relative to the error between personal exposure measurements and the surrogates
described above (Chakrabarti et al., 2004; Lee et al., 2006). Unfortunately, this method
of exposure assessment is impossible: it would be prohibitively expensive and unacceptably intrusive to expect hundreds of thousands of free-living human subjects to agree to
wear personal monitors over their entire adult life, while awake and while sleeping. In
the absence of these ‘gold standard’ point exposure measurements over the participants’
entire exposure history, validation data are necessary for valid estimation and inference of
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relative risks. The available external validation study includes measurements of personal
and ambient P M2.5 between 1998-2002 from nine cities throughout the United States
(Kioumourtzoglou et al., 2014) : Atlanta, GA; Baltimore, MD; Boston, MA; Los Angeles, CA; Research Triangle Park (RTP), NC; Elizabeth, NJ; Houston, TX; Seattle, WA;
Steubenville, OH. The number of subjects in these studies ranged between 15 and 201,
with sampling session durations between 2 to 12 days. The exposure of primary interest,
personal exposure to P M2.5 of ambient origin, corresponds to P M2.5 from outdoor sources
of AP only (Sheppard et al., 2005). This quantity cannot be directly assessed, but is estimated by adjusting the available measurements, which measure AP from both outdoor
and indoor sources together, with a measurement of the ratio of indoor to outdoor SO42−
(Sarnat et al., 2002; Wilson et al., 2000). The latter data were available in 5 of the 9
cities included in the validation study.
In these validation data, two types of surrogate monthly P M2.5 exposure measurements were available for each subject, just as in the NHS AP cohort — the monthly
ambient P M2.5 concentration from the nearest EPA AQS monitor and the smoothed
monthly outdoor P M2.5 concentration, using the nationally expanded spatio-temporal
model (Paciorek et al., 2009; Yanosky et al., 2014) linked to participants’ geocoded residential address. Both of these surrogate exposures measured personal exposure to P M2.5
of ambient origin, the true point exposure of interest here, with a substantial amount
of error; the correlations between these surrogates and the true point exposure ranged
from 0.29 to 0.60. The calibration factors, estimated as the slopes from the regression
of personal P M2.5 of ambient origin on the surrogate exposures, were 0.31 for the nearest EPA monitor exposure and 0.54 for the spatio-temporal model predicted exposure
(Kioumourtzoglou et al., 2014), suggesting that risk estimates will be attenuated if either
of the surrogate exposures is used in the analysis, since only when the calibration factor
is 1, there is no bias in the effect estimate (Carroll et al., 2006).
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After excluding younger subjects due to their age discrepancy with the NHS AP cohort,
40% of the validation study subjects had more than one pair of measurements of personal
and surrogate exposures. The median and interquartile range (IQR) of the duration of
time spanned by these repeated measurements were 6.0 and 5.0 months, respectively.
Thus, even with the most detailed exposure validation data available for use with U.S.
populations, it would not be possible to validate any function of the exposure history of
interest, such as the 12-month moving average. The new method is developed to permit
valid analysis of these data, making it possible to obtain accurate estimates of the hazard
ratio using the methods developed below.

3

FUNCTIONS OF MIS-MEASURED TIME VARYING EXPOSURE HISTORIES

3.1

The Estimator β̂corr

The model of interest here is the Cox model (Cox, 1972) for censored survival data. We
consider the following hazard rate function for the survival time, T, of an individual:

λ(t; {c(v), v ≤ t}, {W(v), v ≤ t}) = λ(t; x(t), Z(t)) = λ0 (t) exp(βx0 x(t) + βz0 Z(t)),

(1)

where λ0 (t) is the baseline hazard function and β = (βx , βz ) is a (p+q)-vector of regression
coefficients. The p-dimensional time-varying exposure vector x(t) is a function of timevarying point exposure histories {c(v), v ≤ t}, which are subject to error, and the qdimensional time-varying error-free covariate vector Z(t) is a function of the covariate
histories {W(v), v ≤ t}. For example, Z(t) may be set to be the most recent measurement
in the histories, i.e., Z(t) = W(t), but often other functions of the histories may be needed
to fully adjust for confounding by W(t).
8
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In AP research, the moving average exposure of a − b duration x(t) is a major focus,
and at time tk of a discrete time scale (t0 , t1 , · · · , tk , · · · , tm ) is given by

x(tk ) =

k−a+1
X

c(tj ) × I(tj )
,
Pk−a+1
j=k−b+1 I(tj )
j=k−b+1

(2)

where I(tj ) is an indicator function for whether the exposure was measured at time tj ,
and a, b are positive integers with b ≥ a. For the 12-month moving average exposure as
motivated by the data at hand, a = 1, b = 12 and the time scale is in months. Instead of
observing the time-varying point exposure histories {c(t), t0 ≤ t ≤ tm }, the NHS measures
the surrogate exposure histories {C(t), t0 ≤ t ≤ tm }, where, in particular, the surrogate
Pk−a+1
C(tj )×I(tj )
Pk−a+1
a − b moving average exposure is X(tk ) =
. As discussed more
j=k−b+1
I(t )
j=k−b+1

j

heuristically in the previous section, it is not possible to validate X(t) because it is a
function of the individual histories of exposures and few exposures have been repeatedly
validated in the same study participants. Hence, we propose a method for obtaining an
estimate of x(t) from {C(t), t0 ≤ t ≤ tm } in the main study using the limited point
exposure data available in the validation study. The corrected hazard ratio estimator
follows by substituting x̂(t) for x(t) in (1).
The method is developed for the main/external validation study design. The main
study consists of data {{Ci (t), t0 ≤ t ≤ tm }, {Wi (t), t0 ≤ t ≤ tm }, Ti , Di }, i = 1, · · · , n1 ,
and {Ci (t), Wi (t)} is measured at a discrete grid of time points (t0 , t1 , · · · , tm ). Here
Ti is the follow-up time, which is defined as the minimum of the potential failure time
Ti0 , the potential censoring time Vi , and the administrative end of follow-up, t∗ , i.e.,
Ti = min(Ti0 , Vi , t∗ ). The validation study consists of data {ci (t), Ci (t), Wi (t)}, i =
n1 + 1, · · · , n1 + n2 , while {ci (t), Ci (t), Wi (t)} is measured less frequently, typically, as
in our case study, no more than at two time points. If case status, Di , is all-cause
mortality as in the data motivating this research, all validation study participants are
alive and censored, i.e. Di = 0 for all the validation subjects, and Ti is known as well,
9
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i = n1 + 1, · · · , n1 + n2 .
In the main study/external validation study design, transportability needs to be assumed, that is, the parameters of measurement error model that are later used for bias
correction can reasonably be assumed to be the same as those which produced the mismeasured data in the main study (Carroll et al., 2006). In addition, we make the standard
conditional independence assumption of measurement error modeling methods,

λ(t; {c(v), v ≤ t}, {C(v), v ≤ t}, {W(v), v ≤ t}) = λ(t; {c(v), v ≤ t}, {W(v), v ≤ t}),

(3)

implying that the surrogate exposure histories {C(v), v ≤ t} have no association with
the outcome given the true exposure histories {c(v), v ≤ t} (Prentice, 1982). In addition,
following Prentice (1982), we assume the censorship satifies λ(t, {C(v), v ≤ t}, {W(v), v ≤
t}, no censorship in [0, t)) = λ(t, {C(v), v ≤ t}, {W(v), v ≤ t}).
Then, it follows that

λ(t; {C(v), v ≤ t}, {W(v), v ≤ t})
= Ec [λ(t; {c(v), v ≤ t}, {C(v), v ≤ t}, {W(v), v ≤ t})|T ≥ t, {C(v), v ≤ t}, {W(v), v ≤ t}]
= Ec [λ(t; {c(v), v ≤ t}, {W(v), v ≤ t})|T ≥ t, {C(v), v ≤ t}, {W(v), v ≤ t}] ,

or equivalently,

λ(t; {C(v), v ≤ t}, {W(v), v ≤ t})
= Ex(t) [λ(t; x(t), X(t), Z(t))|T ≥ t, {C(v), v ≤ t}, {W(v), v ≤ t}]
= Ex(t) [λ(t; x(t), Z(t))|T ≥ t, {C(v), v ≤ t}, {W(v), v ≤ t}] ,

where the expectation Ec is calculated over the true exposure histories {c(v), v ≤ t}, and
the expectation Ex(t) is calculated over the true exposure x(t).
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Hence, for time tk , conditional on {C(t), t ≤ tk } and {W(t), t ≤ tk }, (1) induces

λ(tk ; {C(t), t ≤ tk }, {W(t), t ≤ tk })
= λ0 (tk ) exp(βz0 Z(tk )) · Ex(tk ) [exp(βx0 x(tk ))|{C(t), t ≤ tk }, {W(t), t ≤ tk }, T ≥ tk ]
≈ λ0 (tk ) exp(βz0 Z(tk )) · exp(βx0 · Ex(tk ) [x(tk )|{C(t), t ≤ tk }, {W(t), t ≤ tk }, T ≥ tk ]), (4)

where the approximation in (4) is exact when, in each risk set, (x(tk )|{C(t), t ≤ tk },
{W(t), t ≤ tk }) is normal with homoscedastic covariance matrix. Otherwise, it will hold
approximately when, in each risk set, (x(tk )|{C(t), t ≤ tk }, {W(t), t ≤ tk }) is normal and
βx0 Σx (C(t), W(t))βx is small, or, βx is small with either homoscedastic covariance matrix
or small βx0 Σx (C(t), W(t))βx (Prentice, 1982; Liao et al., 2011).
When, as here, the a − b moving average exposure is of interest, i.e., x(tk ) =
Pk−a+1

j=k−b+1

1
·
b−a+1

c(tj ), (4) can be written as

λ(tk ; {C(t), t ≤ tk }, {W(t), t ≤ tk })
0

≈ λ0 (tk ) exp(βz0 Z(tk )) · exp(β x · Eck [ck |Ck , Wk , T ≥ tk ]),

(5)

where ck = (c(tk−b+1 ), · · · , c(tk−a+1 )), Ck = (C(tk−b+1 ), · · · , C(tk )), Wk = (W(tk−b+1 ),
· · · , W(tk )), β x =

1
1
b−a+1 b−a+1

⊗ βx with 10b−a+1 = (1, 1, · · · , 1)1×(b−a+1) . For ease of no-

tation, we assume that exposure is never missing over times tk−b+1 , · · · , tk−a+1 , otherwise,
missing exposure can be accommodated by (2). Note that ck = (c(tk−b+1 ), · · · , c(tk−a+1 ))
for the a − b moving average, although the surrogate exposure histories are available up to
time tk and before time tk−b+1 . This is because x(tk ) doesn’t depend on (c(tk−a+2 ), · · · , c(tk ))
for a ≥ 2 and the integrals with regard to these variables are equal to one.
We assume a linear measurement error model for the point exposures at time t is given
by
E(c(t)|C(t), W(t)) = α0 (t) + α01 (t)C(t) + α02 (t)W(t),

(6)
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where dim(α0 (t)) = p × 1, dim(α1 (t)) = p × p, dim(α2 (t)) = q × p. Note that (6) implies
the following localized error assumption (Zucker and Spiegelman, 2008) for any j ≤ k in
a risk set:

E(c(tj )|{C(t), t ≤ tk }, {W(t), t ≤ tk }) = E(c(tj )|C(tj ), W(tj ))

(7)

= α0 (tj ) + α01 (tj )C(tj ) + α02 (tj )W(tj ).

This assumption will typically not be empirically verifiable in the main study/external
validation study design because of the typical lack of repeatedly validated point exposures within subjects. Then, for the a − b moving average exposure, the following set of
measurement error models needs to be estimated in each risk set,


α01 (tk−b+1 )C(tk−b+1 )

α02 (tk−b+1 )W(tk−b+1 )

+
 α0 (tk−b+1 ) +


 α0 (tk−b+2 ) + α01 (tk−b+2 )C(tk−b+2 ) + α02 (tk−b+2 )W(tk−b+2 )
E[ck |Ck , Wk , T ≥ tk ] = 


···


α0 (tk−a+1 ) + α01 (tk−a+1 )C(tk−a+1 ) + α02 (tk−a+1 )W(tk−a+1 )






 , (8)





where α0 (tj ), α1 (tj ), α2 (tj ), j ∈ [k − b + 1, k − a + 1] are estimated in each risk set.
Then, (5) can be written as

λ(tk ; {C(t), t ≤ tk }, {W(t), t ≤ tk }) ≈ λ0 (tk ) exp(βx0 x̂(tk ) + βz0 Z(tk ))

with x̂(tk ) =

1
b−a+1

Pk−a+1

j=k−b+1 [α̂0 (tj )

(9)

+ α̂01 (tj )C(tj ) + α̂02 (tj )W(tj )]. Once x̂(tk ) are es-

timated in the main study using the measurement error model (6) fit in the validation
study, the corrected point estimates β̂corr of β = (βx , βz ) are obtained from fitting the
ordinary Cox model (1) with x̂(tk ).
The details of the algorithm is given below for the a − b moving average exposure.
1. Order the r unique failure times that occur in the main study as tk1 < tk2 < · · · < tkr ,
12
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where (k1 , k2 , · · · , kr ) is a subset of indices on the entire time scale. Identify the
subjects who belong to each of the r risk sets Rm (tkd ), d = 1, 2, · · · , r, in the main
study. Generate the risk process indicator Ym (i, tkd ) = I(Ti ≥ tkd ).
2. Find the r risk sets Rv (tkd ), d = 1, 2, · · · , r, which consist of the subjects in the
validation study who are at risk at time tkd . Generate the risk process indicator
Yv (i, tkd ) = I(Ti ≥ tkd ). Estimate ψ̂ kd (tj ) = {α̂0kd (tj ), α̂1kd (tj ), α̂2kd (tj )}, j ∈
[kd − b + 1, kd − a + 1], by running the regression using the most recently observed
exposures c∗ (tj ) on C∗ (tj ), W∗ (tj ) prior to time tj from the subjects in Rv (tkd ).
Since the validation data set is usually small, there will typically not be enough
data to estimate the models for some tj in the later risk sets. Hence, it will often
to be necessary to estimate only ψ̂ kd (tkd ) = {α̂0kd (tkd ), α̂1kd (tkd ), α̂2kd (tkd )}, d =
1, 2, · · · , r in the validation study, approximating ψ̂ kd (tj ) by ψ̂ kl (tkl ), where l ∈
(1, 2, · · · , r) and tkl is the closest failure time to tj . This approximation assumes,
for a fixed tj , ψ kd (tj ) are the same in all the risk sets Rv (tke ), where ke ≥ kd ≥ j.
3. Estimate x̂i (tkd ) =

1
b−a+1

Pkd −a+1

j=kd −b+1 [α̂0kd (tj )

+ α̂01kd (tj )C∗i (tj ) + α̂02kd (tj )Wi∗ (tj )] for

each subject i in each risk set Rm (tkd ) in the main study, d = 1, 2, ..., r.
4. Fit the usual Cox model on (x̂i (tkd ), Zi (tkd ), Ym (i, tkd ), Ti , Di ) to get the measurement error corrected estimator β̂corr , which solves
n1 Z t∗
X
i=1

0






 x̂i (ψ̂, t)


 S(1) (β, ψ̂, t)
Ni ( dt) = 0,

 − (0)

S (β, ψ̂, t) 


Zi (t)

(10)

Pn1
0
0
(1)
i=1
Ym (i, t) exp{βx x̂i (ψ̂, t)+βz Zi (t)}, and S (β, ψ̂, t) =
P 1
 x̂i (ψ̂, t) 
n1 −1 ni=1
Ym (i, t) 
 exp{βx0 x̂i (ψ̂, t) + βz0 Zi (t)}, with the counting proZi (t)
cess Ni (t) = I(Ti ≤ t, Di = 1).
where S (0) (β, ψ̂, t)
= n1 −1
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Unlike the algorithm proposed in Liao et al. (2011), this algorithm constructs functions
of the exposure histories from the point exposures, here the monthly point exposures, to
utilize the limited information in the validation study as previously discussed.

3.2

Asymptotic Properties Of β̂corr

The arguments for approximate consistency of β̂corr are similar to that given in Web Appendix B.1 of Liao et al. (2011) and will not be repeated here. The asymptotic normality
of β̂corr follows similarly to the results in Web Appendix B.2 of Liao et al. (2011), that
is, the asymptotic covariance of β̂corr is given by

ˆ β̂corr ) =
Var(

1 −1
Î Ĥβ,ψ Î−1
β
n1 β

i−1
h P
1 ∂Uβi (β|ψ̂)
where Iˆβ−1 = n11 ni=1
β=β̂corr , Ĥβ,ψ = Ĥβ +
∂β
P 1
Ĥβ = n11 ni=1
Ũβi (β, ψ̂)Ũ0βi (β, ψ̂)|β=β̂corr , with

Ũβi (β, ψ̂) =Uβi (β|ψ̂) −

(11)

1
Û∗ (β, ψ)V̂ψ Û∗ (β, ψ)0 ,
n1 n2

n1
X
Dj Ym (i, Tj ) exp(β 0 x̂i (Tj ) + β 0 Zi (Tj ))
1
(0)
n1 S (β, ψ̂, Tj )

j=1

2






 x̂i (ψ̂, Tj )

 S(1) (β, ψ̂, Tj )

−
,
· 

(0) (β, ψ̂, T ) 

S


j
Zi (Tj )



 x̂i (Ti )


and here, Uβi (β|ψ̂) = Di 
−

 Zi (Ti )





S(1) (β,ψ̂,Ti )
S (0) (β,ψ̂,Ti ) 

is the score equation for each



subject i, with ψ̂ = (ψ̂ kl (tj ), l = 1, 2, · · · , r; j = kl − b + 1, · · · , kl − a + 1), dim(ψ̂) = p ×
P 1 ∂Uβi (β|ψ)
(p+q+1)r×(b−a+1) and dim(Uβi ) = (p+q)×1. Û∗ (β̂, ψ̂) = ni=1
|(β,ψ)=(β̂corr ,ψ̂) ,
∂ψ
with dim(Û∗ ) = (p + q) × p(p + q + 1)r × (b − a + 1). Cov(ψ̂) can be estimated by

1
V̂ ,
n2 ψ̂

with dim(Vψ̂ ) = p(p + q + 1)r(b − a + 1) × p(p + q + 1)r(b − a + 1) and V̂ψ̂ is constructed
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as
n2
∂Uψi,kd (ψ)
1 X
V̂ψ̂ =
n2
∂ψ

"

i=1

#−1 "

#"
#−1
n2
n2
∂Uψi,kd (ψ)
1 X
1 X
0
Uψi,kd (ψ) ⊗ Uψi,kd (ψ)
n2
n2
∂ψ
i=1

where, in the validation study, ψ̂ solves

ψ=ψ̂

,

i=1

Pn2

i=1

Uψi,kd (ψ) = 0, with Uψi,kd (ψ) = (U0α0 i,kd (ψ),

U0α1 i,kd (ψ), U0α2 i,kd (ψ)) is defined as follows
Uα0 i,kd (ψ) = Yv (i, tkd )[ci (tj ) − α0kd (tj ) − α1kd (tj )Ci (tj ) − α2kd (tj )Wi (tj )]0
Uα1 i,kd (ψ) = Yv (i, tkd )Ci (tj )[ci (tj ) − α0kd (tj ) − α1kd (tj )Ci (tj ) − α2kd (tj )Wi (tj )]0
Uα2 i,kd (ψ) = Yv (i, tkd )Wi (tj )[ci (tj ) − α0kd (tj ) − α1kd (tj )Ci (tj ) − α2kd (tj )Wi (tj )]0 (12)

for d = 1, · · · , r, i = 1, · · · , n2 , j = kd − b + 1, · · · , kd − a + 1, dim(Uα0 i,kd ) = 1 ×
p × (b − a + 1), dim(Uα1 i,kd ) = p × p × (b − a + 1), dim(Uα2 i,kd ) = q × p × (b − a + 1),
dim(Uψi,kd (ψ)) = p × (p + q + 1) × (b − a + 1), Uψi = (Uψi,k1 , Uψi,k2 , · · · , Uψi,kr ) and
dim(Uψi ) = p × (p + q + 1)r × (b − a + 1).
Since the risk sets in the validation study are small, the bias-corrected robust covariance estimator proposed by Mancl and DeRouen (2001) is used for V̂ψ̂ to improve the
performance of the variance estimator. It will be shown that the coverage probability
was close to the nominal level of 95% in our simulation studies with this bias-corrected
variance estimator in the next section.

4

SIMULATION STUDIES

We conducted finite sample simulation studies under scenarios arising within a main
study/external validation study design. Since there is no other method that handles the
data structure considered here, results for the new estimator are compared to the naive
estimator. Motivated by our data, the NHS AP cohort and nine city validation study,
estimation and inference for the 12-month moving average exposure with a = 1 and
15
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b = 12 was the focus. Following the motivating data, we set the study duration to t∗ = 84
months (7 years) of follow-up. Both the rare disease and the common disease scenarios
were considered. In the rare disease scenario, the cumulative incidence of the outcome
was set at 1%, and the sample size for the main study and the validation study was set
to n1 = 50000 and n2 = 500, respectively. In the common disease scenario, the sample
size for the main study and the validation study was set to n1 = 1000 and n2 = 500,
respectively, while the cumulative incidence was set to 50%, thereby fixing the number of
cases to be the same in the two scenarios in order to make the results more comparable
with one other. In addition, to more closely follow our data, we also studied a scenario
with an 8% cumulative incidence and a sample size of n1 = 100000 for the main study and
n2 = 100 for the validation study. All simulation results are based on 1000 replications,
where the corresponding 95% nominal coverage is [93.6%, 96.4%].
We first generated the surrogate exposure Ci ∼ M V N (µC , ΣC ), where Ci is a
m−vector with m as the number of the observation time points, µC is the mean vector and ΣC is a covariance matrix. Without loss of generality, we consider a simple case
|j−l|τ

with µC = 0 and ΣC such that ΣC (j, l) = 1 if j = l and ΣC (j, l) = ρI

if j 6= l, with

τ ∈ [0, 1], and ρI as the intra-class correlation. Under this assumed damped exponential
(DEX) covariance structure (Munoz et al., 1992), τ̂ = 0.30 in the case study. When
τ = 0, a compound symmetry (CS) covariance structure is obtained, and the intra-class
correlation ρICS was set at 0.3, 0.6, 0.9. When τ = 1, an AR(1) structure is obtained. To
put these two covariance scenarios on an equal footing, we set the average of the intraclass
correlation coefficients between the possible time points, ρ̄IAR , over [0, t∗ ] equal to ρICS ,
R t∗
i.e., t1∗ 0 (ρIAR )t dt = ρICS . Solving this equation, when t∗ = 84, we obtained values of
ρIAR as 0.963, 0.987, 0.997, as would occur between two measurements adjacent in time,
and at two measurements the farthest apart, when one corresponds to t = 1 and the other
to t = 84, the correlation between these two would be 0.042, 0.329, and 0.809.
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Next, the true exposure was generated as cij = α0 (j) + α1 (j)Cij + eij , where eij ∼
N (0, ∆j ), where ∆j is the measurement error variance, characterized by ∆j = α12 (j)( ρ12 −
1), with ρ = Corr(cij , Cij ) describing the extent of measurement error between two point
exposures taken at a single time within the same subject. α0 (j) and α1 (j) were set
to step functions as

α0 (j) =



 1.2,

 1.5,

if

1 ≤ j ≤ 40

if

41 ≤ j ≤ 84

,

α1 (j) =



 0.5,

if

1 ≤ j ≤ 40


 0.7,

if

41 ≤ j ≤ 84

. In the main

study, we generated pairs (cij , Cij ) at multiple time points tj for each subject i. Because
validation study subjects will only have one or two pairs of measurements, to have r
pairs of measurements for each validation subject i, we first generated a vector Ui of 84
random numbers in [0, 1] and sorted them. Then, the pairs of measurements with the
r smallest elements of Ui were retained in the validation study for each subject i. For
example, if r = 2, and the first two elements of Ui had the rank of 15 and 24 among the
84 random numbers generated, then (ci (15), Ci (15)) and (ci (24), Ci (24)) were included in
the validation study for this subject.
The 12-month moving average exposure x(t) and X(t) was then generated as xi (tk ) =
Pk
Pk
1
1
j=k−11 ci (tj ), Xi (tk ) = 12
j=k−11 Ci (tj ) for 1 ≤ k ≤ m for the time points {t0 , t1 , t2 ,
12
· · · , tm }, m = 84. For simplicity, we used the cumulative average exposure for the first
12 months, then the 12-month moving average exposure for all 72 months following.
Otherwise, as in the analysis to appear in the next section, we would need to exclude data
from the first 12 months from the main study analysis, in order to be able to calculate a
full 12 months of the 12-month moving average exposure for all study subjects from the
start.
We generated the survival time data based on xi (t), following Web Appendix A.2 in
Liao et al. (2011). Since each validation study subject has only a few measurements, the
validation study risk sets can end up with small sample sizes. In addition to using a
bias-corrected robust covariance estimator (Mancl and DeRouen, 2001) to improve finite
sample performance in both the simulation study and the data analysis, we also grouped
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the risk sets to ensure that they each had at least s observations, with s = 10 here, to
further stabilize the results. This idea of grouping risk sets is similar to that used in the
follow-up time regression calibration method proposed by Zhao and Prentice (2014).
Table 1 presents the results for the common and rare disease scenarios under AR(1)
covariance, with 1 and 5 measurements per validation study subject. These simulations
show that the corrected estimator had much smaller bias than the naive estimator in
both point and interval estimates in all the scenarios we explored. Most of the corrected
estimator’s 95% coverage probabilities were within the nominal 95% coverage bounds of
[93.6%, 96.4%] for 1000 replications, while a few were slightly out of range. The simulation
results under a CS covariance structure are presented in Supplementary Table 1 and
showed the similar performance, with slightly less bias observed under AR(1) compared to
CS for the same average correlation over the observed period. In Figure 1, we plotted the
relative bias in β̂corr by the validation study size under AR(1) covariance with ρ̄IAR = 0.6.
The analogous plot for CS covariance with ρICS = 0.6 is presented in Supplementary
Figure 1. The new method had slightly less bias in the rare disease scenario (dashed line)
than in the common disease scenario (solid line). It can be seen that bias was significantly
reduced as the size of the validation study increased.
Because the damped exponential (DEX) covariance structure fit our data better than
CS or AR(1) (Munoz et al., 1992), with ρ̂I = 0.56 and τ̂ = 0.30, we conducted further simulations with this structure. To closely match the data motivating this research, the cumulative incidence rate was set to 8%, the main study sample size was
n1 = 100000, and each subject had 84 monthly measurements. We set α0 (j) and α1 (j) to
α0 (j) =



 0.5,

 0.3,

if

1 ≤ j ≤ 40

if

41 ≤ j ≤ 84

,

α1 (j) =



 0.2,

if

1 ≤ j ≤ 40


 0.5,

if

41 ≤ j ≤ 84

, similar to what had been observed

in the nine city validation study. We studied several combinations of the validation study
sample size (n2 ) and the number of measurements per validation study subjects (R) to
explore how the size of the validation study and the number of repeated measurements
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Table 1: Results for the simulation study of 12-month moving average exposure with
a AR(1) covariance structure, for different intra-class correlations (ρIAR ) and different
amounts of measurement error (ρ).
ρ̄IAR

ρ

0.3

0.4
0.6
0.9
0.4
0.6
0.9
0.4
0.6
0.9

0.6

0.9

0.3

0.6

0.9

0.3

0.6

0.9

0.3

0.6

0.9

0.4
0.6
0.9
0.4
0.6
0.9
0.4
0.6
0.9

0.4
0.6
0.9
0.4
0.6
0.9
0.4
0.6
0.9
0.4
0.6
0.9
0.4
0.6
0.9
0.4
0.6
0.9

ˆ β̂])
Estimated β̂(SE[
Relative Bias(%)
Naive
Corrected
Naive Corrected
There is 1 measurement per validation study subject
n1 = 1000,
n2 = 500,
Common disease
0.322( 0.049) 0.449( 0.119)
-35.5
-10.3
0.326( 0.050) 0.472( 0.094)
-34.8
-5.7
0.329( 0.049) 0.485( 0.076)
-34.2
-3.1
0.324( 0.048) 0.457( 0.121)
-35.3
-8.7
0.328( 0.048) 0.476( 0.092)
-34.5
-4.9
0.327( 0.048) 0.483( 0.074)
-34.6
-3.5
0.325( 0.047) 0.459( 0.118)
-34.9
-8.2
0.326( 0.047) 0.474( 0.091)
-34.9
-5.3
0.329( 0.047) 0.485( 0.073)
-34.2
-3.1
n1 = 50000,
n2 = 500,
Rare disease
0.348( 0.047) 0.478( 0.129)
-30.4
-4.4
0.347( 0.048) 0.495( 0.097)
-30.6
-0.9
0.344( 0.048) 0.498( 0.074)
-31.1
-0.5
0.342( 0.045) 0.482( 0.127)
-31.6
-3.6
0.347( 0.045) 0.499( 0.095)
-30.5
-0.2
0.347( 0.046) 0.500( 0.070)
-30.6
0.1
0.345( 0.044) 0.481( 0.128)
-31.0
-3.7
0.348( 0.044) 0.499( 0.093)
-30.5
-0.3
0.345( 0.045) 0.498( 0.069)
-31.0
-0.5
There are 5 measurements per validation study subject
n1 = 1000,
n2 = 500,
Common disease
0.321( 0.049) 0.469( 0.082)
-35.7
-6.1
0.325( 0.049) 0.479( 0.076)
-35.0
-4.3
0.327( 0.049) 0.482( 0.073)
-34.6
-3.5
0.326( 0.048) 0.478( 0.080)
-34.7
-4.5
0.326( 0.048) 0.481( 0.074)
-34.7
-3.7
0.326( 0.048) 0.481( 0.071)
-34.9
-3.9
0.322( 0.047) 0.471( 0.078)
-35.5
-5.9
0.326( 0.047) 0.482( 0.073)
-34.8
-3.7
0.328( 0.047) 0.485( 0.070)
-34.4
-3.0
n1 = 50000,
n2 = 500,
Rare disease
0.346( 0.047) 0.495( 0.080)
-30.7
-1.0
0.345( 0.048) 0.497( 0.073)
-31.0
-0.6
0.346( 0.048) 0.499( 0.069)
-30.8
-0.2
0.347( 0.045) 0.498( 0.078)
-30.7
-0.4
0.346( 0.045) 0.499( 0.070)
-30.8
-0.2
0.345( 0.046) 0.498( 0.066)
-31.0
-0.3
0.346( 0.044) 0.496( 0.076)
-30.8
-0.9
0.345( 0.044) 0.497( 0.069)
-31.1
-0.6
0.346( 0.045) 0.500( 0.065)
-30.8
-0.1

95% CI Coverage(%)
Naive
Corrected

5.5
5.9
6.4
4.5
5.0
4.1
3.9
3.6
5.2

88.3
93.9
96.2
89.2
94.9
95.3
90.8
92.9
95.5

9.2
10.8
9.0
5.8
7.8
8.4
5.3
6.7
5.6

92.6
96.1
96.1
93.4
96.4
96.5
93.2
96.0
95.1

4.8
5.9
6.8
5.2
4.1
4.3
3.1
3.5
3.8

92.0
94.7
95.2
94.1
95.1
94.6
92.6
94.9
96.1

10.6
11.0
9.9
7.5
8.1
7.3
6.5
5.8
6.2

95.0
95.0
95.6
95.6
94.7
95.7
95.9
95.6
94.8

True β = 0.5, the study duration t∗ = 84, the number of simulation replications B = 1000.
In the common disease situation, the cumulative incidence was about 50% with n1 = 1000.
In the rare disease situation, the cumulative incidence was about 1% with n1 = 50000.
R t∗
ρ̄IAR = t1∗ 0 (ρIAR )t dt with t∗ = 84, ρIAR = 0.963, 0.987, 0.997 respectively.
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AR(1) structure ( ρIAR = 0.6 , τ = 1 )

0

●

ρ = 0.4
ρ = 0.6
ρ = 0.9

−4

●

−6

●

−8

^
Bias of βcorr (%)

−2

●

●

−10

Common disease (50%)
Rare disease (1%)
1

2

3

4

5

The number of measurements per subject in the validation study (n2 = 500)

Figure 1: Plot for relative bias in relation to the validation study size for AR(1) covariance
structure, β = 0.5.
for fixed validation study size affected the bias. The results are presented in Table 2
for several plausible correlations describing the extent of measurement error between the
true exposure and the surrogate exposure, with excellent finite sample performance of the
corrected estimator evident. The bias was less than 5% when the correlation between the
true exposure and the surrogate exposure was greater than 0.6, as was the case for the
spatio-temporal predicted P M2.5 of ambient origin in relation to personal P M2.5 exposure of ambient origin in the nine city validation study. When the correlation between
the true exposure and the surrogate exposure was lower than 0.6, we saw somewhat more
bias. As shown in Table 2, when the total person-time n2 R of the validation study was
constant, for example, when n2 R = 200, the bias was similar as n2 and R were varied.
The bias in both the point and interval estimates was significantly reduced when the total
person-time in the validation study n2 R increased.
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Table 2: Results for the simulation study of 12-month moving average exposure with a
DEX covariance structure, for intra-class correlation ρIDEX = 0.56, τ = 0.30. n1 = 100000.
n2

R

200

1

100

2

40

5

20

10

500

1

100

5

100

10

ρ
0.4
0.6
0.9
0.4
0.6
0.9
0.4
0.6
0.9
0.4
0.6
0.9
0.4
0.6
0.9
0.4
0.6
0.9
0.4
0.6
0.9

Estimated
Naive
0.242( 0.016)
0.242( 0.016)
0.241( 0.016)
0.241(0.016)
0.242(0.016)
0.242(0.016)
0.241( 0.016)
0.242(0.016)
0.242( 0.016)
0.241( 0.016)
0.241( 0.016)
0.241( 0.016)
0.241( 0.016)
0.242( 0.016)
0.243( 0.016)
0.241(0.016)
0.242(0.016)
0.242(0.016)
0.242(0.016)
0.242(0.016)
0.241(0.016)

ˆ β̂])
β̂(SE[
Corrected
0.428( 0.158)
0.475( 0.105)
0.493( 0.051)
0.425(0.158)
0.476(0.105)
0.495(0.051)
0.422(0.156)
0.474(0.102)
0.495(0.051)
0.428( 0.160)
0.476( 0.106)
0.493( 0.052)
0.458( 0.103)
0.488( 0.072)
0.498( 0.041)
0.451(0.105)
0.482(0.074)
0.496(0.043)
0.468(0.077)
0.490(0.056)
0.496(0.037)

Percent Bias (%)
Naive Corrected
-51.6
-14.4
-51.5
-5.0
-51.8
-1.3
-51.7
-15.0
-51.6
-4.7
-51.6
-0.9
-51.8
-15.6
-51.5
-5.2
-51.7
-0.9
-51.7
-14.4
-51.8
-4.8
-51.9
-1.4
-51.7
-8.4
-51.6
-2.4
-51.5
-0.3
-51.8
-9.7
-51.6
-3.6
-51.5
-0.7
-51.7
-6.3
-51.6
-2.1
-51.7
-0.9

95% CI Coverage (%)
Naive
Corrected
0.0
86.5
0.0
91.5
0.0
95.5
0.0
85.5
0.0
92.1
0.0
96.0
0.0
85.2
0.0
92.4
0.0
95.8
0.0
84.8
0.0
92.5
0.0
95.2
0.0
90.4
0.0
94.1
0.0
96.1
0.0
87.9
0.0
94.4
0.0
95.9
0.0
91.2
0.0
95.4
0.0
94.3

True β = 0.5, the study duration t∗ = 84, the number of simulation replications B = 1000.
n2 is the number of subjects in the validation study.
R is the number of measurements per validation study subject.
The cumulative incidence was about 8%.
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5

DATA ANALYSIS

We applied the new method to the analysis of the NHS AP study described in Section
2 (Hart et al., 2015). While the method can be applied to any AP constituent exposures, including P M2.5 , P M10 and P M2.5−10 , and even multiple error-prone exposures in
a single model where p > 1, the goal here was to estimate the prospective association between chronic P M2.5 exposure and all-cause mortality, hence p = 1. The spatio-temporal
predicted P M2.5 (Paciorek et al., 2009; Yanosky et al., 2014) exposure was used as the
surrogate exposure, although as noted previously, the method can be applied to adjust for
bias due to measurement error when the nearest EPA monitor exposure is the surrogate,
as well. The data from the nine city validation study, including personal P M2.5 exposure
of ambient origin, the gold standard, and the surrogate, the spatio-temporal predicted
P M2.5 , were available and utilized to allow the measurement error correction. During the
follow-up period of 2000 to 2006, 7,538,226 person-months were observed among 108,767
nurses, during which time 8,617 deaths occurred from all causes excluding accidents. The
12-month moving average exposure, the exposure metric of interest, was calculated at
every person-month from the monthly spatio-temporal predicted P M2.5 . In the nine city
validation study, there were 184 person-months observed among 100 subjects aged 54 and
87 years old. All of these person-months met the conditions that the pair of true exposure
and surrogate exposure were available and that the age variable was not missing. Since
we used age as the time scale in the Cox model, as is more suitable for prospective epidemiologic studies of chronic disease incidence and mortality (Korn et al., 1997), in this
risk set regression calibration-type method, the age of subjects from the validation study
needed to be matched with the age of subjects from the NHS AP cohort, the main study,
to form the appropriate risk sets, hence younger subjects in the validation study were excluded from the analysis. Basic statistics for monthly P M2.5 in the NHS AP cohort and
the validation study are given in Table 3, together with the age distribution, indicating a
22
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good concordance in both studies. The Pearson correlation between the spatio-temporal
predicted P M2.5 and personal P M2.5 exposure from ambient origin was 0.65, and the
Spearman correlation was 0.67, indicating a moderate amount of measurement error in
the point exposures.
Table 3: Basic statistics of P M2.5 exposure in the NHS AP cohort and the validation
study used in our analysis.

Variable
Monthly personal P M2.5
of ambient origin (µg/m3 )
Monthly spatio-temporal
predicted P M2.5 (µg/m3 )
Age (in years)

Nurses’ Health Study
(n1 = 108, 767)
(Person-month=7,538,226)
Mean(SD) or % (min, max)

Nine city validation study
(n2 = 100)
(Person-month=184)
Mean(SD) or % (min, max)

-

-

10.1(4.4)

(2.6, 22.8)

11.9 (4.1)
69.0 (7.3)

(0.79, 39.8)
(53.5, 87.3)

16.1(4.6)
70.8 (7.8)

(6.6, 24.4)
(54.0, 85.4)

We first estimated the hazard ratio in a basic model adjusted for a limited set of
potential confounders: calendar year, season and region, where season was grouped into
two categories: October-March as the heating season and April-September as the cooling
season, and U.S. census region was grouped into four levels — Northeast, Midwest, West,
and South. Then, we fit a multivariate model that included a much larger set of potential confounders, including smoking status (current/former/never), pack-years (number
of packs/day multiplied by number of years of cigarette smoking), family history of MI
(yes or no), BMI (kg/m2 ), hypercholesterolemia (yes or no), median family income in
census tract of residence (in $1,000), median house value in census tract of residence (in
$1,000), physical activity (< 3, 3 to < 9, 9 to < 18, 18 to < 27, ≥ 27 MET hr/week), race
(caucasian v.s. not), Alternate Healthy Eating Index (AHEI) (Chiuve et al., 2008), individual level socioeconomic status (nurses education level (RN degree v.s. not), parental
occupations (housewife mother at age 16 v.s. not; professional or manager father at age
16 v.s. not), marital status (married v.s. not), and husband’s education (less than high
school, high school, greater than high school)). The most recent measurement of the full
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covariate history was used except for pack-years which was entered as a cumulative total
exposure.
Kioumourtzoglou et al. (2014) reported significant heterogeneity by season in the
measurement error model fit to the nine city validation study, requiring us to include an
interaction term between season and P M2.5 in the measurement error model used in the
analysis, as follows:

E(c(t)|C(t), W(t)) = α0 (t)+α1 (t)∗C(t)+α2 (t)∗W1 (t)+α3 (t)∗W2 (t)+α4 (t)∗C(t)∗W2 (t), (13)

where c(t) represents personal P M2.5 exposure of ambient origin, C(t) represents spatiotemporal predicted P M2.5 , W1 (t) represents region, W2 (t) represents season. The method
readily accommodates functions of C(t) and W(t), for example, C(t) ∗ W2 (t) in the measurement error model (6), since the derivation in (5) still holds when such functions are
included. Since the additional covariates in the multivariate model were only available
in the NHS AP cohort, we have assumed that they are not associated with the measurement error model conditional on the covariates already included and thus they are not
considered for entry in (13).
The results of the analysis are given in Table 4. The uncorrected RR (95% CI) for
PM2.5 measured by the spatio-temporal predicted P M2.5 exposure was 1.20(1.11,1.29) per
10µg/m3 in the basic model, and 1.13(1.05,1.22) in the multivariate model, demonstrating
some confounding by some of the additional covariates. Since the validation study was
small (n2 = 100 with 184 person-month observations), we grouped the risk sets to stabilize
the results, to ensure that, as described in Section 4, each risk set would have a minimum
of s observations. Different choice of s results in different compositions and numbers of
risk sets. To determine the optimal value of s, we conducted a 20-fold cross-validation
approach in the validation study, and calculated the mean square error, mean absolute
error, and Pearson and Spearman correlations of the prediction error, for each choice of
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s ranging from 10 to 100. The mean square error and the mean absolute error were the
smallest, and the correlations were the biggest, when s = 85, resulting in 2 risk sets, where
the first risk set had 86 person months with age ranging from 53.8 to 70.5 years, and the
second had 98 person months with age ranging from 70.6 to 87.0 years. We proceeded
with the analysis with this optimized s.
As always, we must assess whether the assumptions necessary for valid application of
the method are satisfied. In particular, at least one of the sets of conditions following
equation (4) must be satisfied. One of these sets of conditions is that the residuals of
the measurement error models for each risk set as given by equation (6) are normal and
βx2 σ 2 is small, where σ 2 is the residual variance of the model (13) in each risk set. The
diagnostic plots for normality are displayed in Figure 2, with the left column of the plots
corresponding to the first risk set and the right column of the plots corresponding to the
second risk set. The residual variance is around 10.0 in both risk sets, and if βx = 0.165
as estimated from the multivariate model in Table 4, then βx2 σ 2 = 0.27 < 0.5. The
cutoff 0.5 was suggested by Kuha (1994) as the maximum value of βx2 σ 2 allowed for valid
application of regression calibration. The normality plots and histograms of the residuals
suggest close conformation to the normal distribution, with the p-value for the ShapiroWilk test of normality being 0.23 for the younger risk set and 0.17 for the older risk set.
Given normality and small βx2 σ 2 , the approximation needed in (4) will hold.
The corrected estimates were then calculated using our new method, and the results
are presented in Table 4, together with the uncorrected estimates. In the basic model,
the corrected RR (95% CI) per 10µg/m3 PM2.5 was de-attenuated to 1.27(1.08,1.48) from
1.20(1.11,1.29), p = 0.003. The de-attenuation was similar for the multivariate model, in
which the corrected RR (95% CI) per 10µg/m3 PM2.5 was increased to 1.18(1.02,1.36)
from the uncorrected 1.13(1.05,1.22). These results demonstrate that the risk of all-cause
mortality from chronic exposure to P M2.5 of ambient origin has been under-estimated
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Figure 2: Normality plots for the residuals from the measurement error model (13). Left:
Risk set 1; Right: Risk set 2.
when the spatio-temporal predicted exposure is used as the surrogate in the main study,
and that our method is able to produce point and interval estimates of relative risk even
with the limited validation data available. In the NHS AP cohort, the mean of the 12month moving average P M2.5 exposure was 12.0µg/m3 (Hart et al., 2015). Thus, this
analysis provides evidence that P M2.5 exposure below the current U.S. EPA standard of
12µg/m3 is associated with an increased risk of all-cause mortality, and that measurement
error correction should be implemented in studies whenever possible to obtain valid point
and interval estimate.

6

CONCLUSION AND DISCUSSION

Motivated by the NHS AP study, one of a small number of large scale prospective cohorts
available worldwide in which chronic AP effects can be assessed, we have developed a
RRC-type measurement error correction method for survival data analysis to obtain a
consistent estimate of the hazard ratio for functions of mis-measured time-varying expo26
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Table 4: Hazard ratios for P M2.5 (per 10µg/m3 ) in relation to all-cause mortality in the
NHS AP cohort.
Method
Uncorrected
Corrected

Basic modela
Estimate (S.E.) RR (95% C.I.)
0.181(0.039)
1.20(1.11,1.29)
0.236(0.081)
1.27(1.08,1.48)

p-value
< 0.001
0.003

Multivariate modelb
Estimate (S.E.) RR (95% C.I.)
0.125(0.039)
1.13(1.05,1.22)
0.165(0.073)
1.18(1.02,1.36)

p-value
0.002
0.024

a

Adjusted for age (in months), calendar year, region, and season.
Adjusted for age (in months), calendar year, region, season, smoking status, pack-years, family
history of MI, BMI, hypercholesterolemia, median family income in census tract of residence, median house value in census tract of residence, physical activity, race, Alternate Healthy Eating Index
(AHEI), individual level socioeconomic status (nurses education level, parental occupations, marital
status, and husband’s education).
b

sure histories in the presence of limited validation data. Although motivated by studies
of the health effects of chronic AP, the statistical methods developed in this paper have
far wider applicability, as many longitudinal cohort studies in epidemiology focus on survival data endpoints such as cancer incidence and cause-specific mortality, in relation to
exposures that are functions of mis-measured time-varying exposure histories. This fully
general case arises, in addition to in AP epidemiology, e.g. Thomas et al. (1993), in occupational epidemiology, including studies of radiation exposure, e.g. Samet et al. (1991),
and widely throughout nutritional epidemiology, e.g. Hu et al. (1999). The derivation
given in (4) and (5) applies to all linear exposure metrics, including, importantly, the
Pk
1
cumulative average exposure, defined as x(tk ) = tk −t
j=0 c(tj ), commonly used in nu0
P
tritional epidemiology, and the cumulative total exposure, defined as x(tk ) = kj=0 c(tj ),
commonly used in occupational epidemiology. When either of these exposure functions
is used, as given by equation (4), equation (5) will follow with ck = (c(t0 ), · · · , c(tk )),
Ck = (C(t0 ), · · · , C(tk )), Wk = (W(t0 ), · · · , W(tk )), β x =

1
1
tk −t0 k+1

⊗ βx for the cu-

mulative average exposure and β x = 1k+1 ⊗ βx for the cumulative total exposure with
10k+1 = (1, 1, · · · , 1)1×(k+1) . Then, in the algorithm given in Section 3.1, the range of the
index j in Step 2 and the functional form in Step 3 can be altered as needed for the cumulative average exposure and the cumulative total exposure. The asymptotic variance
in Section 3.2 will automatically apply with a different functional form for x̂(t).
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This paper focused on the a − b month moving average exposure as motivated by
our case study, where the positive integers a and b are fixed constants. More research
is being conducted for estimating the latency parameters, a and b, for different timevarying exposure metrics while simultaneously quantifying the hazard ratio for exposure
in relation to health outcome (Wang et al., 2015). For example, in the a − b month
moving average exposure, instead of pre-specifying a and b as constants, a and b can
be estimated together with the hazard ratio, βx , for different exposure metrics with and
without exposure measurement error.
In the NHS AP cohort analysis, the age range of nurses was 33.8 years (406 months),
during which time 367 unique failure times occured, with age(months) as the time scale.
The age range of the subjects in the validation study was 31.4 years (377 months). Thus,
we had at least one case occurring at nearly every age(months) of follow-up. For any
time tj on the observed time scale, we approximated ψ̂ kd (tj ) by ψ̂ kl (tkl ) for d ≥ l ∈
{1, 2, · · · , r}, where tkl is the closest failure time to tj . In addition, we assumed that
ψ̂ kd (tj ) was the same in all risk sets Rv (tke ), where ke ≥ kd ≥ j, using the largest risk set
closest to tj to calculate ψ̂ kd (tj ) for tkd > tj . This approximation becomes better when
the disease is rarer, which explained the slightly better performance of the rare disease
scenario over the common disease scenario in our simulation studies. If more validation
data become available in the future, it will be possible to fine-tune the validation study
parameter estimation and better ensure the robustness of the estimator.
This is the first method developed for estimation and inference in survival data analysis of the effects of functions of mis-measured exposure histories, a common scenario in
environmental, occupational, and nutritional epidemiology. The asymptotic variance estimator was derived. As shown in Xie et al. (2001) and Liao et al. (2011), some asymptotic
bias in the estimator was expected due to the approximation in equation (4). Even, for
example, when the data for (x(tk )|{C(t), t ≤ tk }, {W(t), t ≤ tk }) are generated from the
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multivariate normal distribution at baseline such as in our simulations, the distribution
would be expected to deviate from normality in later risk sets, inducing some degree of
asymptotic bias. A detailed simulation study demonstrated improvements in the performance of the method as the validation study size increased. We suggest grouping the
validation study risk sets so that the number of observations in each risk set will not
be too small to stabilize the results, and proposed a data-driven cross-validation method
to optimize the risk set size. When possible, a larger validation study with three or
more measurements per subject would be desirable to further reduce bias, although the
simulations indicated the results were reasonable for currently available validation study
sizes.
For outcomes other than mortality, for example, lung cancer incidence, {Ti , Di } may
be unknown in an external validation study, and the rare disease assumption will need to
be invoked, setting Di = 0. While our method is designed for the main study/external
validation study design as motivated by our case study, it can be easily extended to
the main study/internal validation study design (Zucker and Spiegelman, 2008), where
the validation study is a sub-sample of the main study and thus the outcome status is
also available in the validation study together with both true and surrogate exposures.
Technical details for this extension will be covered in a future paper on measurement
error correction analysis for the cumulative exposure to radon in relation to lung cancer
mortality among uranium miners, updating Samet et al. (1991).
A user-friendly SAS macro has been developed and posted at https://www.hsph.harvard.edu/donna-spiegelman/software/rrc-macro/. The macro supports five commonly used exposure metrics which arise in environmental, occupational and nutritional
epidemiology: the a−b time unit moving average exposure, as is our focus here, the cumulative average exposure, the cumulative total exposure, the simple updated exposure (i.e.,
time-varying point exposure), and the time-independent exposure. In order to facilitate
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valid estimation for U.S. AP studies, the nine city validation study has been posted at
http://www.hsph.harvard.edu/pm2-5-validation-dataset/download-validationdataset/.

7

SUPPLEMENTARY MATERIAL

Supplementary Table 1 : Results for the simulation study of 12-month moving average exposure with a compound symmetry covariance structure, for different intra-class
correlations (ρICS ) and different amounts of measurement error (ρ).
Supplementary Figure 1 : Plot for relative bias in relation to the validation study size
for CS covariance structure.
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